4DMedical Limited (ASX: 4DX) says it has received Therapeutic Goods Administration (TGA) approval in Australia for its CT:VQ™ technology. The company states that CT:VQ™ enables ventilation-perfusion imaging using non-contrast methods derived from routine chest CT scans. In its announcements, 4DMedical presents the approval as enabling non-contrast ventilation-perfusion imaging to be available in Australia, positioning the approach as a potential option for patients who need ventilation-perfusion assessment without the use of contrast agents.
The releases identify the technology as focusing on ventilation-perfusion imaging and emphasize that it is based on information obtained from standard CT imaging rather than requiring a separate contrast-enhanced imaging workflow. The announcements do not provide detailed efficacy results, clinical trial outcomes, or broader regulatory conditions within the provided text. The filings also do not specify the exact intended clinical indications, reimbursement status, or timeline for commercial rollout beyond the fact of TGA approval.
